

Figure. S1. Time course of liver injury following liver I/R. WT (B6), CCR2^{-/-} and CD11c-DTR mice pre-treated with DT or PBS 12 h earlier underwent 1 h of ischemia and serum ALT was measured 0, 6, 12 or 24 h later. Data represent means \pm SEM. N = 5 mice per group.




Figure S2. Reconstitution of adoptively transferred cDCs. CD11c-DTR mice pre-treated with DT were injected i.v. with 1×10^7 WT, IL10^{-/-}, or TLR9^{-/-} cDCs just prior to I/R. Ischemic liver CD45⁺ NPCs were isolated 12 h later and assessed for the presence of injected cDCs. Data are representative of 2 independent experiments, n = 4-6 mice per group.




Figure S3. cDC cytokine production. WT, TLR9^{-/-} and IL10^{-/-} cDCs were purified by immunomagnetic beading and cultured with recombinant HMGB1 (rHMGB1, 20 µg/ml) or conditioned (Con) media. Supernatant levels of IL-6 and TNF were determined 18 h later using a cytometric bead array. Data represent means ± SEM and are representative of 2 independent experiments, n = 5 mice per group. *, p < 0.05; **, p < 0.01.




Figure S4. cDC purity and maturation. Spleen cDCs used for adoptive transfer experiments were isolated from Flt3L-treated WT mice as described in Materials and Methods. The purity (CD11c^{hi}MHCII^{hi}) and maturation (CD40, 80, 86 and MHCII) of freshly isolated cDCs was determined by FACS. Isotype (shaded histograms), spleen cDCs from untreated WT mice (gray histograms) and cDCs from Flt3L-treated mice (bold histograms). Data are representative of at least 2 independent experiments each with 5 mice.